CS
EPRS

Credit Suisse’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Credit Suisse’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18,494
Closed -$105K – 4776
2015
Q2 		$105K Sell
18,494
-18,655
-50% -$127K ﹤0.01% 4381
2015
Q1 		$333K Buy
+37,149
New +$298K ﹤0.01% 3808

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's EPRS Position: Q3 2015 in Review

Credit Suisse sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2015, closing a stake of 18,494 shares — an estimated $105K sold.

Credit Suisse first reported a position in EPRS in Q1 2015 and held it in 2 quarters. The position peaked at $333K in Q1 2015. 41 funds tracked by Wall St. Rank hold EPRS as of Q3 2015.

  • Credit Suisse reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2015 after selling out during the quarter.
  • Credit Suisse sold 18,494 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2015, an estimated $105K.
  • Credit Suisse first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 2 quarters.
  • Credit Suisse's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $333K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2015.

Based on Credit Suisse's 13F filing for Q3 2015, filed 13 Nov 2015.